Experienced in Virilizing Ovarian Tumor

Dr. Sarah F. Adams

Obstetrics and Gynecology | Gynecologic Oncology
Unm Medical Group Inc
2211 Lomas Blvd Ne, 
Albuquerque, NM 
Experienced in Virilizing Ovarian Tumor
Unm Medical Group Inc
2211 Lomas Blvd Ne, 
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sarah Adams is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Albuquerque, New Mexico. Dr. Adams is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Hernia Surgery, and Hysterectomy.

Her clinical research consists of co-authoring 25 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Obstetrics and Gynecology
Gynecologic Oncology
Licenses
Obstetrics & Gynecology in IL
Hospital Affiliations
Unm Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

UNM MEDICAL GROUP INC
2211 Lomas Blvd Ne, Albuquerque, NM 87106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Tremelimumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: Olaparib, Tremelimumab
Study Phase: Phase 1/Phase 2
A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug, Other
Study Phase: Not Applicable
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

25 Total Publications

Genetic mutation predicts survival after immunotherapy for ovarian cancer.
Genetic mutation predicts survival after immunotherapy for ovarian cancer.
Journal: Nature
Published: July 08, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Karen A. Finkelstein
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Karen A. Finkelstein
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Southwest Women's Oncology Inc

2400 Unser Blvd Se, Suite 28300, 
Albuquerque, NM 
 (10.0 miles away)
505-843-7813
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Karen Finkelstein is a Gynecologic Oncologist and an Oncologist in Albuquerque, New Mexico. Dr. Finkelstein is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hernia Surgery. Dr. Finkelstein is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Sara M. Jordan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Sara M. Jordan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Presbyterian Healthcare Services

1100 Central Ave Se, 
Albuquerque, NM 
 (1.0 miles away)
505-841-1234
Languages Spoken:
English, Arabic, Cantonese, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sara Jordan is a Gynecologic Oncologist and an Oncologist in Albuquerque, New Mexico. Dr. Jordan is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, Oophorectomy, and Hernia Surgery. Dr. Jordan is currently accepting new patients.

Advanced in Virilizing Ovarian Tumor
Dr. Carolyn Y. Muller
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Virilizing Ovarian Tumor
Dr. Carolyn Y. Muller
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Unm Medical Group Inc

2211 Lomas Blvd Ne, 
Albuquerque, NM 
 (0.1 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances

Carolyn Muller is a Gynecologic Oncologist and an Oncologist in Albuquerque, New Mexico. Dr. Muller is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Adams's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile